Review
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Apr 16, 2025; 17(4): 103391
Published online Apr 16, 2025. doi: 10.4253/wjge.v17.i4.103391
Advancements in the diagnosis of biliopancreatic diseases: A comparative review and study on future insights
Eyad Gadour, Bogdan Miutescu, Zeinab Hassan, Emad S Aljahdli, Khurram Raees
Eyad Gadour, Multiorgan Transplant Centre of Excellence, Liver Transplantation Unit, King Fahad Specialist Hospital, Dammam 32253, Saudi Arabia
Eyad Gadour, Internal Medicine, Zamzam University College, School of Medicine, Khartoum 11113, Sudan
Bogdan Miutescu, Department of Gastroenterology and Hepatology, Victor Babes University of Medicine and Pharmacy, Timisoara 300041, Romania
Bogdan Miutescu, Advanced Regional Research Center in Gastroenterology and Hepatology, Victor Babes University of Medicine and Pharmacy, Timisoara 30041, Romania
Zeinab Hassan, Department of Internal Medicine, Stockport Hospitals NHS Foundation Trust, Manchester SK2 7JE, United Kingdom
Emad S Aljahdli, Gastroenterology Division, King Abdulaziz University, Faculty of Medicine, Jeddah 21589, Saudi Arabia
Emad S Aljahdli, Gastrointestinal Oncology Unit, King Abdulaziz University Hospital, Jeddah 22252, Saudi Arabia
Khurram Raees, Department of Gastroenterology and Hepatology, Royal Blackburn Hospital, Blackburn BB2 3HH, United Kingdom
Author contributions: Gadour E and Miutescu B contributed to conceptualization; Raees K, Hassan Z and Aljahdli ES contributed to resources; Miutescu B, Aljahdli ES and Gadour E contributed to writing, reviewing and editing; Raees K, Hassan Z and Gadour E contributed to writing the final manuscript; Miutescu B, Aljahdli ES and Gadour E contributed to supervision; Gadour E and Miutescu B contributed to project administration. All authors read and agreed to the published version of the manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bogdan Miutescu, MD, PhD, Assistant Professor, Department of Gastroenterology and Hepatology, Victor Babes University of Medicine and Pharmacy, Piața Eftimie Murgu 2, Timisoara 300041, Romania. bmiutescu@yahoo.com
Received: November 28, 2024
Revised: February 19, 2025
Accepted: March 8, 2025
Published online: April 16, 2025
Processing time: 147 Days and 15.7 Hours
Abstract

Owing to the complex and often asymptomatic presentations, the diagnosis of biliopancreatic diseases, including pancreatic and biliary malignancies, remains challenging. Recent technological advancements have remarkably improved the diagnostic accuracy and patient outcomes in these diseases. This review explores key advancements in diagnostic modalities, including biomarkers, imaging techniques, and artificial intelligence (AI)-based technologies. Biomarkers, such as cancer antigen 19-9, KRAS mutations, and inflammatory markers, provide crucial insights into disease progression and treatment responses. Advanced imaging modalities include enhanced computed tomography (CT), positron emission tomography-CT, magnetic resonance cholangiopancreatography, and endoscopic ultrasound. AI integration in imaging and pathology has enhanced diagnostic precision through deep learning algorithms that analyze medical images, automate routine diagnostic tasks, and provide predictive analytics for personalized treatment strategies. The applications of these technologies are diverse, ranging from early cancer detection to therapeutic guidance and real-time imaging. Biomarker-based liquid biopsies and AI-assisted imaging tools are essential for non-invasive diagnostics and individualized patient management. Furthermore, AI-driven models are transforming disease stratification, thus enhancing risk assessment and decision-making. Future studies should explore standardizing biomarker validation, improving AI-driven diagnostics, and expanding the accessibility of advanced imaging technologies in resource-limited settings. The continued development of non-invasive diagnostic techniques and precision medicine approaches is crucial for optimizing the detection and management of biliopancreatic diseases. Collaborative efforts between clinicians, researchers, and industry stakeholders will be pivotal in applying these advancements in clinical practice.

Keywords: Biliopancreatic diseases; Endoscopic ultrasound; Endoscopic retrograde cholangiopancreatography; Magnetic resonance cholangiopancreatography; Peroral cholangiopancreatoscopy; Diagnostic advancements; Biomarkers in biliopancreatic diseases; Artificial intelligence in gastroenterology

Core Tip: Recent advancements in the diagnosis of biliopancreatic disease have significantly transformed clinical practice. Enhanced imaging techniques such as endoscopic ultrasound and computed tomography can provide detailed anatomical insights for accurate diagnosis. Additionally, the integration of biomarkers and artificial intelligence technologies can improve early disease detection and diagnostic precision. These innovations facilitate targeted treatment strategies tailored to individual patient needs, ultimately enhancing patient outcomes and quality of life. As the field continues to evolve, ongoing research and collaboration among healthcare professionals will be essential to further refine the diagnostic tools and approaches for biliopancreatic diseases.